Business Wire

Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust

Share

Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty.

Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital.

Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center.

Kyriba’s approach directly addresses the "Trust Gap" – the growing divide between the promise of AI-driven financial transformation and the fear of security and privacy risks. A new Kyriba survey* of CFOs and treasury leaders in the US, UK, France and Japan reveals that while 53% view AI as the most significant transformation to their role over the next five years, 76% are concerned that security or privacy risks could undermine their organization’s financial health.

“While many are racing to churn out ‘autonomous’ finance solutions, we’re hearing what leaders are really saying: adopting AI shouldn’t mean compromising on security, control, or risk standards in finance and treasury. As companies continue to face economic volatility, TAI was designed to optimize liquidity performance with nimble, data-driven insights – plus the assurance of integrity, visibility and ownership,” said Kyriba Chair and CEO Melissa Di Donato.

TAI will be showcased at the company’s annual customer conference, KyribaLive, beginning today in Orlando. Attendees will hear from Kyriba executives, industry leaders, partners and customers, including members of Kyriba’s Co-Innovation Lab that piloted TAI’s agentic AI capabilities such as Sodexo, Koch, Inc. and Mews.

“While leveraging AI to realize greater efficiency is top of mind, the safety and security of our data is paramount. I appreciate seeing firsthand how Kyriba puts transparency and human oversight at the forefront. As a Co-Innovation Lab member, I am optimistic about TAI’s potential to enhance our treasury and payment processes, and look forward to its continued evolution,” said Yoann Kremer, Systems & Projects Manager - Enterprise Liquidity Management, Sodexo.

"Trust is phenomenally important for us at this stage as a key pivot issue for AI adoption – being able to determine if the ‘right’ answer is a ‘true’ answer. Trust is critical right now in helping to build confidence,” said Meaghan Downs, Sr. Analyst, Global Payment Solutions, Koch, Inc.

“As a scale up, we are really nimble and agile and we want to be ahead of the trend. This was a great opportunity to see how we can integrate AI into the treasury workflows by automating the repetitive tasks and focusing our time on being more productive – allowing us to focus on the decisions that we need to make to take the company forward,” said Hemant Godhwani, Head of Corporate Finance & Treasury at Mews.

Transcending traditional financial tools by addressing liquidity challenges, the Trusted AI portfolio also offers innovative solutions like Cash AI, Invoice AI and Fraud Detection AI across Kyriba’s product pillars.

“We’re hearing loud and clear that finance leaders are excited about the potential of automation – but remain skeptical about oversight, ethics and workforce impact. Kyriba’s agentic AI addresses these concerns head on with its embedded and compliant LLM approach designed to augment – not replace – human expertise, which I expect the market will welcome wholeheartedly,” added Kevin Permenter, IDC Senior Research Director, Financial Applications.

Kyriba customers can preview TAI at Kyriba User Groups and KyribaLive Exchange (KLX) events around the world. For dates and locations, visit kyriba.com.

* Survey conducted Feb 18 - Mar 3, 2025 by CensusWide on behalf of Kyriba among 1,000 CFOs, Treasurers and senior financial decisionmakers working at companies with $100M+ in revenue across US, UK, France and Japan.

About Kyriba

Kyriba is the global leader in liquidity performance, empowering CFOs, Treasurers and IT leaders to connect, protect, forecast and optimize their liquidity amid economic complexity. As a secure and scalable SaaS solution trusted by 3,000 customers, Kyriba delivers intelligence and financial automation through innovative technologies – including its trusted agentic AI (TAI) – bringing precision, efficiency, and insight to financial operations. With an expansive ecosystem of banking, technology and consulting partners, Kyriba’s platform powers more than 3 billion bank transactions and $15 trillion in payments across 9,900+ banks annually – helping companies gain enterprise-wide visibility, ensure financial stability, and outperform their business strategy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250513797363/en/

Contacts

Media Contact:
PR@kyriba.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release

Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release

Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye